Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25056409 | 0.81 | PLK1 (0.33) | POLL | |
| SCHEMBL25637788 | 0.81 | DDB1 (0.39) | PKMTDP1MEN1KMT2AMAPT | |
| SCHEMBL25637720 | 0.79 | SIRT6 (0.39) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25637727 | 0.78 | CYP1A2 (0.38) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25637849 | 0.77 | SIRT6 (0.38) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25637647 | 0.77 | SIRT6 (0.39) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25637658 | 0.76 | PKM (0.38) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25637686 | 0.76 | SIRT6 (0.34) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25056359 | 0.75 | PKM (0.38) | PKMTDP1MEN1KMT2ASIRT6 | |
| SCHEMBL25637694 | 0.74 | ALDH1A1 (0.38) | PKMTDP1MEN1KMT2ASIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PKM 2484/4885TDP1 2926/4885MEN1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.